Investment Analysts’ Recent Ratings Changes for Mesa Laboratories (MLAB)

Several analysts have recently updated their ratings and price targets for Mesa Laboratories (NASDAQ: MLAB):

  • 2/10/2018 – Mesa Laboratories was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy. “
  • 2/7/2018 – Mesa Laboratories was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating.
  • 2/7/2018 – Mesa Laboratories was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/31/2018 – Mesa Laboratories was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy. “
  • 1/30/2018 – Mesa Laboratories was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/9/2018 – Mesa Laboratories was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy. “

Mesa Laboratories, Inc. (NASDAQ MLAB) traded up $0.85 during trading hours on Tuesday, reaching $131.98. The company had a trading volume of 17,300 shares, compared to its average volume of 18,425. The company has a market cap of $496.09, a P/E ratio of -131.98 and a beta of 0.52. Mesa Laboratories, Inc. has a one year low of $117.58 and a one year high of $169.80. The company has a quick ratio of 1.64, a current ratio of 2.37 and a debt-to-equity ratio of 0.58.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Wednesday, February 28th will be given a $0.16 dividend. The ex-dividend date is Tuesday, February 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.48%. Mesa Laboratories’s payout ratio is -64.00%.

In related news, Director John Bradley Schmieder sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the director now owns 77,869 shares in the company, valued at approximately $10,299,732.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.70% of the company’s stock.

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Receive News & Ratings for Mesa Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply